Trial Profile
Phase IV Observational Study in Chronic Lymphocytic Leukemia Patients Receiving Ofatumumab in the European Union
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 07 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 08 Mar 2013 Planned number of patients 1 added as reported by ClinicalTrials.gov.
- 19 Oct 2011 New trial record